This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

1. (currently amended) A compound of formula (I):

wherein

P<sup>1</sup> and P<sup>2</sup> independently represent a polymer residue the residue of a polyethylene glycol (PEG) molecule;

 $Z^1$ ,  $Z^2$  and  $Z^3$  independently represent the residue of a biologically active moiety polyclonal, monoclonal, multi-valent, multi-specific, humanized or chimeric antibody, a single chain antibody, a Fab fragment, a Fab' or  $F(ab')_2$  fragment, or an epitope-binding fragment thereof;

X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> independently represent CR<sup>1</sup> or N;

 $A^1$  and  $A^2$  independently represent -CONH-, -NHCO-, -OC(O)N(R<sup>2</sup>)-, -N(R<sup>2</sup>)C(O)O- or -NHCONH-;

B<sup>1</sup>, B<sup>2</sup> and B<sup>3</sup> independently represent -CONH- or -CO-;

 $V^{1}$ , and  $V^{2}$  and  $V^{3}$  independently represent a covalent bond or -(CH<sub>2</sub>)<sub>v</sub>-;

W<sup>1</sup> and W<sup>2</sup> independently represent a covalent bond or -(CH<sub>2</sub>)<sub>w</sub>-;

 $Y^1$ ,  $Y^2$  and  $Y^3$  independently represent -(CH<sub>2</sub>)<sub>y</sub>-;

L<sup>1</sup>, L<sup>2</sup> and L<sup>3</sup> independently represent a spacer group maleimide residue;

M<sup>1</sup> and M<sup>2</sup> independently represent a covalent bond or -(CH<sub>2</sub>)<sub>m</sub>-;

 $R^1$  represents hydrogen or  $C_{1-4}$  alkyl;

R<sup>2</sup> represents hydrogen or C<sub>1-4</sub> alkyl;

n is zero, 1 or 2;

v is 1, 2, 3 or 4; w is 1, 2, 3 or 4; y is 1, 2, 3, 4, 5 or 6; and m is 1, 2 or 3.

- 2. (previously presented) A compound as claimed in claim 1 wherein  $Z^1$ ,  $Z^2$  and  $Z^3$  independently represent the residue of a whole antibody or the residue of a functionally active antibody fragment or derivative.
- 3. (withdrawn) A compound of formula (II):

$$P^{1} \xrightarrow{A^{1}} W^{1} \xrightarrow{X^{1}} V^{1} \xrightarrow{B^{1}} Y^{1} \xrightarrow{L^{11}} M^{1} \xrightarrow{X^{3}} V^{3} \xrightarrow{B^{3}} Y^{3} \xrightarrow{L^{13}} n$$

$$P^{2} \xrightarrow{A^{2}} W^{2} \xrightarrow{X^{2}} V^{2} \xrightarrow{B^{2}} Y^{2} \xrightarrow{L^{12}} n$$
(II)

wherein

 $L^{11}$ ,  $L^{12}$  and  $L^{13}$  represent groups that attach residues  $Z^1$ ,  $Z^2$  and  $Z^3$ , respectively, or that are converted into groups that attach residues  $Z^1$ ,  $Z^2$  and  $Z^3$ , respectively;

 $Z^1$ ,  $Z^2$  and  $Z^3$  independently represent the residue of a biologically active moiety;

 $P^1$  and  $P^2$  independently represent a polymer residue;

X<sup>1</sup>, X<sup>2</sup> and X<sup>3</sup> independently represent CR<sup>1</sup> or N;

A<sup>1</sup> and A<sup>2</sup> independently represent -CONH-, -NHCO-, -OC(O)N(R<sup>2</sup>)-,

 $-N(R^2)C(O)O$ - or -NHCONH-;

B<sup>1</sup>, B<sup>2</sup> and B<sup>3</sup> independently represent -CONH- or -CO-;

 $V^1$ ,  $V^2$  and  $V^3$  independently represent a covalent bond or -(CH<sub>2</sub>)<sub>v</sub>-;

W<sup>1</sup> and W<sup>2</sup> independently represent a covalent bond or -(CH<sub>2</sub>)<sub>w</sub>-;

 $Y^1$ ,  $Y^2$  and  $Y^3$  independently represent -(CH<sub>2</sub>)<sub>y</sub>-;

M<sup>1</sup> and M<sup>2</sup> independently represent a covalent bond or -(CH<sub>2</sub>)<sub>m</sub>-;

 $R^1$  represents hydrogen or  $C_{1-4}$  alkyl;  $R^2$  represents hydrogen or  $C_{1-4}$  alkyl; n is zero, 1 or 2; v is 1, 2, 3 or 4; w is 1, 2, 3 or 4; y is 1, 2, 3, 4, 5 or 6; and m is 1, 2 or 3.

4. (withdrawn) A compound as claimed in claim 3 represented by formula (III):

- 5. (cancelled)
- 6. (withdrawn) A compound as claimed in claim 1 wherein R<sup>1</sup> is hydrogen.
- 7. (previously presented) A compound as claimed in claim 1 wherein n is zero.
- 8. (previously presented) A compound as claimed in claim 1 that is

DiFab'-conjugated N,N'-bis-[4-maleimidylbutyl]-2,3-bis-(3-(methoxy-polyethoxy)-propionylamino)-succinamide;

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

- 9. (withdrawn) A compound as claimed in claim 4 that is
- N,N'-Bis-[4-maleimidylbutyl]-2,3-bis-(3-(methoxy-polyethoxy)-propionylamino)-succinamide;
- 3-Maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or
- 3-Maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.
- 10. (previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.